1. Seroprevalence and risk factors associated with West Nile infection in human in Madagascar: a cross-sectional serological survey
- Author
-
Christophe Rogier, Anne-Claire Dorsemans, Soa Fy Andriamandimby, Marie-Marie Olive, Anaïs Broban, Jean-Michel Heraud, Fanjasoa Rakotomanana, Jean-Pierre Ravalohery, and Seta Andriamamonjy
- Subjects
Geography ,Environmental health ,Seroprevalence ,Serology - Abstract
Background: West Nile virus (WNV) is a vector-borne virus maintained through an arthropod-borne transmission cycle involving bird hosts and Culex mosquito species. The disease affects humans in North America, Europe, Africa and Indian Ocean islands including Madagascar. In Madagascar, despite the surveillance of WNV, unreported WNV encephalitis (WNE) are suspected. In order to improve WNE surveillance efficiency and optimize the available resources we aimed to estimate WNV human seroprevalence in different areas of the island, and to identify the environmental factors and areas favorable to WNV transmission in human.Methods: Between 2011 and 2013, during a national cross-sectional serological survey 1,680 individuals were sampled. Sera were tested for IgG directed against WNV using ELISA and Hemagglutination Inhibition assays. Then, we analyzed human serological results using Generalized Linear Mixed Models, with the individual serological status as the response, and environmental variables and human related factors as explanatory variables. Results : The overall human WNV seropositivity rate was 12.7% (95% CI [11.2-14.4]). Human seroprevalence was positively associated with humid environment (pConclusions: Our results indicate a heterogeneous circulation of WNV in human and highlights that humid environment of the northwestern part of the island is at-risk for WNV circulation whereas cold environment of the highlands is not favorable for WNV transmission in human. The identification of at-risk environments for WNV circulation in humans should help to improve the surveillance of the disease in Madagascar and is a first step to target future studies on acute encephalitis.Trial registration: The protocol was approved by the Malagasy competent authorities, the Malagasy Ethic National Committee (authorization N°066/MSAMP/CE, 26th July 2011).
- Published
- 2021
- Full Text
- View/download PDF